PCS
ACAD icon

Personal CFO Solutions’s Acadia Pharmaceuticals ACAD Stock Holding History

Personal CFO Solutions’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,306
Closed -$302K – 521
2025
Q4 		$302K Sell
11,306
-8
-0.1% -$191 0.05% 367
2025
Q3 		$241K Buy
11,314
+165
+1% +$3.9K 0.04% 434
2025
Q2 		$240K Sell
11,149
-1,003
-8% -$18.6K 0.04% 404
2025
Q1 		$202K Sell
12,152
-78
-0.6% -$1.42K 0.04% 428
2024
Q4 		$224K Buy
+12,230
New +$197K 0.04% 412
2024
Q3 		– Sell
-12,614
Closed -$205K – 562
2024
Q2 		$205K Sell
12,614
-177
-1% -$2.86K 0.03% 506
2024
Q1 		$237K Sell
12,791
-37
-0.3% -$917 0.04% 472
2023
Q4 		$402K Buy
12,828
+20
+0.2% +$478 0.07% 288
2023
Q3 		$267K Buy
12,808
+27
+0.2% +$733 0.05% 351
2023
Q2 		$306K Sell
12,781
-79
-0.6% -$1.76K 0.06% 324
2023
Q1 		$242K Buy
12,860
+14
+0.1% +$267 0.05% 380
2022
Q4 		$205K Sell
12,846
-3,500
-21% -$54.7K 0.04% 419
2022
Q3 		$267K Hold
16,346
– – 0.07% 277
2022
Q2 		$230K Buy
16,346
+500
+3% +$9.33K 0.05% 345
2022
Q1 		$384K Buy
15,846
+1,000
+7% +$24.2K 0.08% 248
2021
Q4 		$347K Sell
14,846
-13,154
-47% -$265K 0.07% 280
2021
Q3 		$465K Buy
28,000
+2,800
+11% +$54K 0.1% 200
2021
Q2 		$615K Hold
25,200
– – 0.13% 159
2021
Q1 		$650K Buy
25,200
+3,400
+16% +$150K 0.14% 133
2020
Q4 		$1.17M Hold
21,800
– – 0.29% 78
2020
Q3 		$1M Buy
21,800
+1,000
+5% +$43.2K 0.33% 51
2020
Q2 		$1.01M Buy
20,800
+3,100
+18% +$149K 0.3% 76
2020
Q1 		$748K Buy
17,700
+8,100
+84% +$334K 0.27% 83
2019
Q4 		$411K Buy
+9,600
New +$418K 0.12% 166

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Personal CFO Solutions's ACAD Position: Q1 2026 in Review

Personal CFO Solutions sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 11,306 shares — an estimated $302K sold.

Personal CFO Solutions first reported a position in ACAD in Q4 2019 and held it in 24 quarters. The position peaked at $1.17M in Q4 2020. 343 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Personal CFO Solutions reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Personal CFO Solutions sold 11,306 Acadia Pharmaceuticals shares in Q1 2026, an estimated $302K.
  • Personal CFO Solutions first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 24 quarters.
  • Personal CFO Solutions's Acadia Pharmaceuticals position peaked at $1.17M in Q4 2020.
  • 343 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Personal CFO Solutions's 13F filing for Q1 2026, filed 30 Apr 2026.